256 related articles for article (PubMed ID: 28238601)
1. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.
Huttner A; Hatz C; van den Dobbelsteen G; Abbanat D; Hornacek A; Frölich R; Dreyer AM; Martin P; Davies T; Fae K; van den Nieuwenhof I; Thoelen S; de Vallière S; Kuhn A; Bernasconi E; Viereck V; Kavvadias T; Kling K; Ryu G; Hülder T; Gröger S; Scheiner D; Alaimo C; Harbarth S; Poolman J; Fonck VG
Lancet Infect Dis; 2017 May; 17(5):528-537. PubMed ID: 28238601
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.
Frenck RW; Ervin J; Chu L; Abbanat D; Spiessens B; Go O; Haazen W; van den Dobbelsteen G; Poolman J; Thoelen S; Ibarra de Palacios P
Lancet Infect Dis; 2019 Jun; 19(6):631-640. PubMed ID: 31079947
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
7. Vaccine Development for Urinary Tract Infections: Where Do We Stand?
Magistro G; Stief CG
Eur Urol Focus; 2019 Jan; 5(1):39-41. PubMed ID: 30093359
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.
Inoue M; Ogawa T; Tamura H; Hagiwara Y; Saito Y; Abbanat D; van den Dobbelsteen G; Hermans P; Thoelen S; Poolman J; Ibarra de Palacios P
Hum Vaccin Immunother; 2018; 14(9):2150-2157. PubMed ID: 29771596
[TBL] [Abstract][Full Text] [Related]
10. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
[TBL] [Abstract][Full Text] [Related]
12. The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli.
Huttner A; Gambillara V
Clin Microbiol Infect; 2018 Oct; 24(10):1046-1050. PubMed ID: 29803843
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Abraham S; Juel HB; Bang P; Cheeseman HM; Dohn RB; Cole T; Kristiansen MP; Korsholm KS; Lewis D; Olsen AW; McFarlane LR; Day S; Knudsen S; Moen K; Ruhwald M; Kromann I; Andersen P; Shattock RJ; Follmann F
Lancet Infect Dis; 2019 Oct; 19(10):1091-1100. PubMed ID: 31416692
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
[TBL] [Abstract][Full Text] [Related]
15. Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.
Bézay N; Wagner L; Kadlecek V; Obersriebnig M; Wressnigg N; Hochreiter R; Schneider M; Dubischar K; Derhaschnig U; Klingler A; Larcher-Senn J; Eder-Lingelbach S; Bender W
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38830375
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
18. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Zhu FC; Hou LH; Li JX; Wu SP; Liu P; Zhang GR; Hu YM; Meng FY; Xu JJ; Tang R; Zhang JL; Wang WJ; Duan L; Chu K; Liang Q; Hu JL; Luo L; Zhu T; Wang JZ; Chen W
Lancet; 2015 Jun; 385(9984):2272-9. PubMed ID: 25817373
[TBL] [Abstract][Full Text] [Related]
20. Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.
Abbanat D; Davies TA; Amsler K; He W; Fae K; Janssen S; Poolman JT; van den Dobbelsteen GPJM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 28971965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]